Aspire Biopharma Holdings, Inc. (ASBP) Earnings History
Net Loss5 years of earnings data (2021–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Aspire Biopharma Holdings, Inc. (ASBP) Earnings Overview
As of June 28, 2026, Aspire Biopharma Holdings, Inc. (ASBP) reported trailing twelve-month net income of -$12M, reflecting +9.9% year-over-year growth. The company earned $-7.87 per diluted share over the past four quarters, with a net profit margin of -394725.1%.
Looking at the long-term picture, ASBP's historical earnings data spans multiple years. The company achieved its highest annual net income of $4M in fiscal 2023.
Aspire Biopharma Holdings, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CRBP (-$85M net income), YCBD (-$3M net income, -10.6% margin), XXII (-$4M net income, -71.7% margin), ASBP has comparable earnings metrics. Compare ASBP vs CRBP →
ASBP Earnings vs Peers
Earnings metrics vs comparable public companies
ASBP Historical Earnings Data (2021–2025)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$24M | -95.3% | -$19M | $-16.38 | -394725.1% | -312016.9% |
| 2024 | -$13M | -380.8% | -$3M | $-18.17 | - | - |
| 2023 | $4M | +33.7% | -$1M | $9.31 | - | - |
| 2022 | $3M | +13210.9% | $-976,345 | $3.72 | - | - |
| 2021 | $-25,475 | - | $-25,480 | $-0.04 | - | - |
Download Data
Export ASBP earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ASBP — Frequently Asked Questions
Quick answers to the most common questions about buying ASBP stock.
What is ASBP earnings per share (EPS)?
ASBP trailing twelve-month (TTM) diluted EPS is $-7.87, reflecting +9.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2021 to 2025 is available in the table on this page.
What is Aspire Biopharma Holdings, Inc.'s net income?
Aspire Biopharma Holdings, Inc. (ASBP) trailing twelve-month net income is $-12M as of 2025. Earnings grew +9.9% year-over-year.
Is ASBP profitable?
ASBP is not currently profitable on a TTM basis, reporting a net loss of $-12M. Net margin is -394725.1%. Investors should monitor for a return to profitability.
What is ASBP's earnings growth rate?
ASBP compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2021 to 2025.
What are ASBP's profit margins?
Aspire Biopharma Holdings, Inc. net profit margin is -394725.1%, operating margin is -312016.9%, and gross margin is -1.9%. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is ASBP growing earnings?
ASBP is growing earnings steadily. YoY EPS growth of +9.9% is consistent with the 5-year CAGR of N/A. TTM net income is $-12M.
What was ASBP's best earnings year?
Aspire Biopharma Holdings, Inc.'s highest annual net income on record is $4M, achieved in fiscal year 2023. Earnings history on this page spans 2021 to 2025 and includes all annual and quarterly figures.
What were ASBP's earnings last quarter?
ASBP's most recent reported quarter was Q1 2026. Net income was $-3M with diluted EPS of $-2.16. For a full breakdown of all quarters, see the quarterly earnings table on this page.